UDP-GlcDH CRISPR Activation Plasmid (h): sc-405002-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UDP-GlcDH CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- UDP-GlcDH CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by UDP-GlcDH CRISPR Activation Plasmid (h) and UDP-GlcDH CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the UGDH transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UDP-GlcDH Antibody (B-4): sc-137058
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UDP-GlcDH CRISPR Activation Plasmid (h) | sc-405002-ACT | 20 µg | $397.00 |
UGDH encodes UDP-glucose 6-dehydrogenase (UDP-GlcDH), a cytosolic oxidoreductase that catalyzes conversion of UDP-glucose to UDP-glucuronic acid, a key activated sugar nucleotide for glycosaminoglycan and proteoglycan biosynthesis. By supplying UDP-glucuronic acid, UDP-GlcDH supports extracellular matrix assembly, cell adhesion and migration programs, and broader glycoconjugate metabolism that influences receptor signaling and tissue remodeling. Altered UGDH activity has been linked to changes in hyaluronan and other glycosaminoglycan composition, with reported associations to tumor cell invasiveness, fibrosis-related matrix remodeling, and inflammatory microenvironment dynamics. As a metabolic gatekeeper for UDP-sugar interconversions, UGDH is frequently studied in pathways connecting nucleotide-sugar availability to mechanotransduction and epithelial–mesenchymal transitions.
UDP-GlcDH CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous UGDH expression without altering the underlying DNA sequence.
UDP-GlcDH CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the UGDH locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the UGDH transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous UDP-GlcDH expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native UGDH locus and enabling the study of UDP-GlcDH-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of UDP-GlcDH pathway restoration in tumor cells with silenced or reduced UGDH expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.